1. U.S. Department of Health and Human Services. 14th report on carcinogens. https://ntp.niehs.nih.gov/whatwestudy/assessments/cancer/roc/index.html#toc1. 2017. Accessed December 1, 2020.
2. WHO-World Health Organization. Overall evaluations of carcinogenicity: an updating of IARC monographs volumes 1 to 42. Lyon (FR); 1987:7. https://monographs.iarc.who.int/wp-content/uploads/2018/06/Suppl7.pdf.
3. Schlingemann J, Burns MJ, et al. The landscape of potential small and drug substance related nitrosamines in pharmaceuticals. J Pharm Sci. 2022;S0022–3549(22):00525–31.
4. FDA-U.S. Food & Drug Administration. FDA announces voluntary recall of several medicines containing valsartan following detection of an impurity. Press Release. https://www.fda.gov/news-events/press-announcements/fdaannounces-voluntary-recall-several-medicines-containing-valsartan-followingdetection-impurity. 2018a. Accessed December 1, 2020.
5. FDA-U.S. Food & Drug Administration. FDA provides update on its ongoing investigation into valsartan products; and reports on the finding of an additional impurity identified in one firm’s already recalled products. Press Release. https://www.fda.gov/news-events/press-announcements/fda-provides-updateits-ongoing-investigation-valsartan-products-and-reports-finding-additional. 2018b. Accessed December 1, 2020.